natgillin/translations-raw huggingface dataset:
The marketing authorisation holder, Eurovet Animal Health BV submitted an application for a type II variation to shorten the withdrawal period in chickens to 6 days for Soludox 500 mg/g powder for use in drinking water for pigs and chickens and associated names, which has been subject to a worksharing procedure by the CMDv according to Article 20 of Commission Regulation (EC) No 1234/2008.
Imetnik dovoljenja za promet z zdravilom, družba Eurovet Animal Health BV, je predložil vlogo za spremembo tipa II za skrajšanje karence pri piščancih na 6 dni za zdravilo Soludox 500 mg/g prašek za uporabo v pitni vodi za prašiče in piščance in povezana imena, ki je bila predmet postopka za delitev dela s strani CMDv, v skladu s členom 20 Uredbe Komisije (ES) št. 1234/2008.
The CVMP concluded a withdrawal period of 9 days is appropriate for chickens for the dose of 20 mg/kg bw for 4 consecutive days.
CVMP je zaključil, da je za odmerek 20 mg/kg telesne mase 4 dni zapored za piščance ustrezna 9-dnevna karenca.
The worksharing procedure (UK/V/xxxx/WS/006) involving Soludox 500 mg/g powder for use in drinking water for pigs and chickens (NL/V/0141/001/WS/002) and Soludox 500 mg/g powder for use in drinking water for pigs and chickens (UK/V/0349/001/WS/002) started on 6 January 2012.
Postopek za delitev dela (UK/V/xxxx/WS/006) za zdravilo Soludox 500 mg/g prašek za uporabo v pitni vodi za prašiče in piščance (NL/V/0141/001/WS/002) in zdravilo Soludox 500 mg/g prašek za uporabo v pitni vodi za prašiče in piščance (UK/V/0349/001/WS/002) se je začel 6. januarja 2012.
Soludox 500 mg/g powder for use in drinking water for pigs and chickens contains doxycycline hyclate as active ingredient.
Zdravilo Soludox 500 mg/g prašek za uporabo v pitni vodi za prašiče in piščance vsebuje zdravilno učinkovino doksiciklinijev hiklat.
On 12 June 2013 the CVMP adopted a final opinion confirming the recommendation included in its opinion of 7 March 2013, that the variation of the marketing authorisations for Soludox 500 mg/g powder for use in drinking water for pigs and chickens (NL/V/0141/001/WS/002) and Soludox 500 mg/g powder for use in drinking water for pigs and chickens (UK/V/0349/001/WS/002) can be granted and a withdrawal period of 9 days is appropriate for chickens for the dose of 20 mg/kg bw for 4 consecutive days.
Odbor CVMP je 12. junija 2013 sprejel končno mnenje, s katerim je potrdil priporočilo, ki je bilo vključeno v mnenje Odbora z dne 7. marca 2013, da je mogoče odobriti spremembo dovoljenj za promet z zdravilom za zdravilo Soludox 500 mg/g prašek za uporabo v pitni vodi za prašiče in piščance (NL/V/0141/001/WS/002) in zdravilo Soludox 500 mg/g prašek za uporabo v pitni vodi za prašiče in piščance (UK/V/0349/001/WS/002) in da je za odmerek 20 mg/kg telesne mase 4 dni zapored za piščance ustrezna 9-dnevna karenca.
Based on the evaluation of the available data the CVMP adopted, on 7 March 2013, an opinion recommending the granting of the variation of the marketing authorisations for Soludox 500 mg/g powder for use in drinking water for pigs and chickens (NL/V/0141/001/WS/002) and Soludox 500 mg/g powder for use in drinking water for pigs and chickens (UK/V/0349/001/WS/002).
Odbor CVMP je na podlagi ocene razpoložljivih podatkov 7. marca 2013 sprejel mnenje, da priporoča odobritev sprememb dovoljenj za promet z zdravilom za zdravilo Soludox 500 mg/g prašek za uporabo v pitni vodi za prašiče in piščance (NL/V/0141/001/WS/002) in zdravilo Soludox 500 mg/g prašek za uporabo v pitni vodi za prašiče in piščance (UK/V/0349/001/WS/002).
Opinion following an Article 131 referral for Soludox 500 mg/g powder for use in drinking water for pigs and chickens and associated names
Mnenje v zvezi z napotitvijo v skladu s členom 130F za zdravilo Soludox 500 mg/g prašek za uporabo v pitni vodi za prašiče in piščance in povezana imena stran 2/2
The European Commission issued a decision on 29 January 2010.
Evropska komisija je odločbo izdala dne 29. januarja 2010.
The CHMP opinion was confirmed after re-examination.
Mnenje CHMP je bilo po ponovni presoji mnenja potrjeno.
When an antibiotic is produced using a natural source, as in this instance, there can be some differences in the composition of the finished product.
Če se antibiotik izdeluje s pomočjo naravnega vira, kot v tem primeru, se lahko pojavijo razlike v sestavi končnega zdravila.
Re-examination
Ponovna presoja
London, 22 October 2009 rev. Doc.
London, 22. oktobra 2009 rev.
However, the Member States were not able to reach an agreement and the German Regulatory Agency referred the matter to the CHMP for arbitration on 8 October 2008.
Vendar države članice niso mogle doseči soglasja, zato je nemška regulatorna agencija dne 8. oktobra 2008 zadevo napotila na CHMP.
This is a procedure when one Member State (the ‘reference Member State', in this instance Germany) assesses a medicine with a view of granting a marketing authorisation that will be valid in this country as well as in other Member States (the ‘concerned Member States', in this instance Austria, Ireland, Italy, Portugal, Spain and the United Kingdom).
To je postopek, ko ena država članica („referenčna država članica“, v tem primeru Nemčija) presoja zdravilo z vidika odobritve dovoljenja za promet, ki bo veljavno v omenjeni državi ter v drugih državah članicah („zadevnih“ državah članicah, v tem primeru v Avstriji, na Irskem, v Italiji, na Portugalskem, v Španiji in v Združenem kraljestvu).
On 25 June 2009, the European Medicines Agency (EMEA) completed an arbitration procedure following a disagreement among Member States of the European Union regarding the authorisation of the medicine Teicoplanin Hospira.
Evropska agencija za zdravila (EMEA) je dne 25. junija 2009 končala postopek arbitraže, do katerega je prišlo po nesoglasju med državami članicami Evropske unije glede odobritve zdravila Teicoplanin Hospira.
After having considered the grounds for this request, the CHMP re-examined the initial opinion, and confirmed the recommendation for the refusal of the marketing authorisation on 22 October 2009.
Po proučitvi podlage za to zahtevo je CHMP ponovno pregledal prvotno mnenje in dne 22. oktobra 2009 potrdil priporočilo za zavrnitev odobritve dovoljenja za promet z zdravilom.
Dr Barbara Van Zwieten-Boot
dr. Karl Broich dr. Barbara Van Zwieten-Boot
It is use to treat patients with serious infections due to Grampositive bacteria.
Uporablja se za zdravljenje bolnikov s hudimi okužbami z grampozitivnimi bakterijami.
Questions and answers on the referral for Teicoplanin Hospira powder and solvent for injection containing 200 or 400 mg teicoplanin
Vprašanja in odgovori v zvezi z napotitvijo za zdravilo Teicoplanin Hospira prašek in vehikel za injiciranje z 200 ali 400 mg teikoplanina
Together, the cell wall and membrane form a barrier between the bacterial cell contents and the external environment.
Celična stena in membrana skupaj tvorita pregrado med vsebino celične stene bakterij ter zunanjim okoljem.
Initial Assessment
Prvotna presoja
Teicoplanin Hospira is a generic medicine based on a ‘reference medicine' authorised in Germany (Targocid 400 mg).
Zdravilo Teicoplanin Hospira je generično zdravilo na podlagi „referenčnega zdravila“, ki je že odobreno v Nemčiji (Targocid 400 mg).
Gram-positive bacteria include bacteria such as staphylocci (Staphylococcus aureus), streptococci (Streptococcus pneumoniae), Listeria, Clostridium difficile.
Grampozitivne bakterije so bakterije, kot so stafilokoki (Staphylococcus aureus), streptokoki (Streptococcus pneumoniae), Listeria, Clostridium difficile.
Medicines are bioequivalent when they produce the same levels of the active substance in the body.
Zdravili sta biološko enakovredni, ko v telesu dosegata enake ravni zdravilne učinkovine.
Based on the evaluation of the currently available data and the scientific discussion within the Committee, the CHMP concluded that the benefits of Teicoplanin Hospira do not outweigh its risks, and therefore the marketing authorisation should not be granted in the concerned Member States.
Na podlagi ocene trenutno razpoložljivih podatkov in znanstvenih razprav v odboru CHMP je ta zaključil, da koristi zdravila Teicoplanin Hospira ne odtehtajo z njim povezanih tveganj, zato se dovoljenje za promet z zdravilom v zadevnih državah članicah ne sme odobriti.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of Teicoplanin Hospira do not outweigh its risks, and the marketing authorisation cannot be granted in Germany and in other Member States of the EU (Austria, Ireland, Italy, Portugal, Spain and the United Kingdom).
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji EMEA je zaključil, da koristi zdravila Teicoplanin Hospira ne odtehtajo z njim povezanih tveganj, zato dovoljenja za promet z zdravilom ni mogoče odobriti v Nemčiji in drugih državah članicah EU (v Avstriji, na Irskem, v Italiji, na Portugalskem, v Španiji in v Združenem kraljestvu).
There were also concerns that the composition of the teicoplanin in Teicoplanin Hospira was different to that in Targocid, with a potential impact on the effectiveness of the medicine.
Obstajali so tudi zadržki, da je bila sestava teikoplanina v zdravilu Teicoplanin Hospira drugačna kot v zdravilu Targocid, kar lahko vpliva na učinkovitost zdravila.
Dr Ian Hudson
dr. Patrick Salmon dr. Ian Hudson
The grounds for the referral were concerns from Ireland and the United Kingdom that Teicoplanin Hospira had not been shown to be bioequivalent to Targocid.
Razlogi za napotitev so bili zadržki Irske in Združenega kraljestva, da za zdravilo Teicoplanin Hospira ni bila dokazana biološka enakovrednost zdravilu Targocid.
The company that makes Teicoplanin Hospira, Hospira UK Limited, requested a re-examination of the opinion.
Izdelovalec zdravila Teicoplanin Hospira, družba Hospira UK Limited, je zahteval ponovno presojo mnenja.
Why was Teicoplanin Hospira reviewed?
Zakaj je bilo zdravilo Teicoplanin Hospira pregledano?
Company responses provided on: 23 January 2009 and 27 May 2009
23. januar 2009 in 27. maj 2009 3. september 2009
Teicoplanin Hospira can only be used in patients who cannot receive penicillin or cephalosporins antibiotics, or if these antibiotics have stopped working or the infection is due to a Staphylococcus that is resistant to other antibiotics.
Zdravilo Teicoplanin Hospira se lahko uporablja le pri bolnikih, ki ne smejo prejeti penicilinskih ali cefalosporinskih antibiotikov, ali kadar ti antibiotiki ne učinkujejo več ali ko okužbo povzroči bakterija Staphylococcus, ki je odporna proti tem antibiotikom.
These bacteria can cause skin infections, lung infections, joint and bone infections, heart infections or infections of the urinary tract (structures that carry urine).
Te bakterije lahko povzročijo okužbe kože, pljuč, sklepov in kosti, srčne mišice ali sečil (struktur za odvajanje urina).
It works by stopping the bacteria making their cell walls and by disrupting their cell membranes.
Deluje tako, da v bakterijah prekine izdelavo celične stene in poruši celično membrano.
Teicoplanin Hospira can also be used to prevent infections in patients undergoing surgery of the bones, joint or blood vessels.
Zdravilo Teicoplanin Hospira se lahko uporablja tudi za preprečevanje okužb pri bolnikih s kirurškim posegom na kosteh, sklepih ali ožilju.
Hospira UK Limited submitted Teicoplanin Hospira to the German Regulatory Agency for a decentralised procedure.
Družba Hospira UK Limited je nemški regulatorni agenciji predložila vlogo za pridobitev dovoljenja za promet z zdravilom Teicoplanin Hospira po decentraliziranem postopku.
By disrupting this barrier, teicoplanin kills the bacteria that are causing the infection.
Ko teikoplanin prekine to pregrado, uniči bakterije, ki povzročajo okužbo.
Teicoplanin Hospira is an antibiotic.
Zdravilo Teicoplanin Hospira je antibiotik.
What is Teicoplanin Hospira?
Kaj je zdravilo Teicoplanin Hospira?
This is because teicoplanin in Teicoplanin Hospira is made by fermentation, using a bacterium called Actinoplanes to produce the antibiotic.
To je posledica izdelave teikoplanina v zdravilu Teicoplanin Hospira s postopkom fermentacije in bakterijo Actinoplanes, ki tvori antibiotik.
The active substance in Teicoplanin Hospira, teicoplanin, is an antibiotic that belongs to the group ‘glycopeptides'.
Zdravilna učinkovina zdravila Teicoplanin Hospira, teikoplanin, je antibiotik iz skupine „glikopeptidov“.
Referral start date:
Odgovori družbe, poslani dne:
Adopted at the 14-17 January 2019 PRAC
Sprejeto na seji odbora PRAC, 14.-17. januarja 2019
Gabapentin - Dysphagia (EPITT no 19296)
Gabapentin - disfagija (EPITT št. 19296)
The risk of interference is higher in children and patients with renal impairment and increases with higher doses.
Tveganje za vpliv je večje pri otrocih in bolnikih z ledvično okvaro ter se povečuje z večjimi odmerki.
For medicinal products for oral use containing ≥150 microgram biotin per dose unit and medicinal products for parenteral use containing ≥60 microgram biotin per dose unit
Za zdravila za peroralno uporabo, ki vsebujejo ≥ 150 mikrogramov biotina na enoto odmerka, in zdravila za parenteralno uporabo, ki vsebujejo ≥ 60 mikrogramov biotina na enoto odmerka
Interference with clinical laboratory tests
Vpliv na klinične laboratorijske preiskave
[Product name] contains <quantity> biotin per <dose unit>.
Zdravilo [ime zdravila] vsebuje <količina> biotina na <enota odmerka>.
Please inform your doctor or the laboratory personnel, if you are taking such products.
Obvestite zdravnika ali laboratorijsko osebje, če jemljete tovrstne izdelke.
You should also be aware that other products that you may take, such as multivitamins or supplements for hair, skin, and nails could also contain biotin and affect the results of laboratory tests.
Poleg tega upoštevajte, da lahko tudi drugi izdelki, ki jih morda jemljete, na primer multivitamini ali prehranska dopolnila za lase, kožo in nohte, vsebujejo biotin in vplivajo na rezultate laboratorijskih preiskav.
Biotin - Interference with clinical laboratory tests (EPITT no 19156)
Biotin - vpliv na klinične laboratorijske preiskave (EPITT št. 19156)
If you are about to undergo laboratory testing you must tell your doctor or the laboratory personnel that you are taking or have recently taken [Product name], because biotin may affect results of such tests.
Če bodo pri vas opravljali laboratorijske preiskave, morate zdravnika ali laboratorijsko osebje obvestiti, da jemljete ali ste pred kratkim jemali zdravilo [ime zdravila], saj lahko biotin vpliva na rezultate teh preiskav.
When interpreting results of laboratory tests, possible biotin interference has to be taken into consideration, especially if a lack of coherence with the clinical presentation is observed (e.g. thyroid test results mimicking Graves' disease in asymptomatic patients taking biotin or false negative troponin test results in patients with myocardial infarction taking biotin).
Pri interpretaciji rezultatov laboratorijskih preiskav je treba upoštevati morebitni vpliv biotina, zlasti ob opaženem neskladju s klinično sliko (npr. rezultati preiskave ščitnice pri asimptomatskih bolnikih, ki jemljejo biotin, kažejo na Gravesovo bolezen ali lažno negativni rezultati preiskave troponina pri bolnikih z miokardnim infarktom, ki jemljejo biotin).
Your doctor may ask you to stop taking [Product name] before performing laboratory tests.
Zdravnik vam lahko naroči, da morate pred laboratorijskimi preiskavami prenehati jemati zdravilo [ime zdravila].
The laboratory personnel should be consulted when ordering laboratory tests in patients taking biotin.
Pri naročanju laboratorijskih preiskav za bolnike, ki jemljejo biotin, se je treba posvetovati z laboratorijskim osebjem.
Biotin may interfere with laboratory tests that are based on a biotin/streptavidin interaction, leading to either falsely decreased or falsely increased test results, depending on the assay.
Biotin lahko vpliva na laboratorijske preiskave, ki temeljijo na medsebojnem delovanju med biotinom in streptavidinom, kar privede do lažno znižanih ali lažno zvišanih rezultatov preiskav, odvisno od testa.
Depending on the test, the results may be falsely elevated or falsely low due to biotin.
Odvisno od preiskave so rezultati zaradi biotina lahko lažno zvišani ali lažno znižani.
Alternative tests not susceptible to biotin interference should be used, if available, in cases where interference is suspected.
Kadar obstaja sum na vpliv, je treba uporabiti druge preiskave, na katere biotin nima vpliva, če so na voljo.
• Difficulty swallowing
Občasni: disfagija
Warnings and precautions
Bolezni prebavil
Assessment of efficacy issues
Ocena vprašanj učinkovitosti
ACVIM Consensus Statement 2007.
Izjava o soglasju ACVIM 2007.
Because of the delta, a control group is necessary.
Zaradi delte je kontrolna skupina nujna.
A placebo effect must always be assumed to be present.
Vedno je treba domnevati, da je učinek placeba prisoten.
Member State / EEA
Država članica/EGP
SCIENTIFIC CONCLUSIONS AND GROUNDS FOR REFUSAL OF THE VARIATION
ZNANSTVENI ZAKLJUČKI IN PODLAGA ZA ZAVRNITEV SPREMEMBE
Following the absence of agreement between the Reference Member State and one Concerned Member State (Belgium) at Day 90 of the CMD(v) procedure, the matter was referred to CVMP.
Zaradi odsotnosti sporazuma med referenčno državo članico in eno zadevno državo članico (Belgijo) je bila na 90. dan postopka CMD(v) zadeva napotena na CVMP.
P. 157-162.
str. 157-162.
However, the prolonged duration of effect over the course of 6 months, in addition to its efficacy during the entire inter-dosage interval, was noted.
Vendar pa je bilo opaženo podaljšano trajanje učinka v obdobju šest mesecev poleg učinkovitosti v celotnem intervalu med uporabama.
P. 542-558.
str. 542-558.
In the context of the current study, a white coat effect should impact both groups equally in order to allow a treatment effect to emerge.
V okviru trenutne študije bi moral učinek bele halje v enaki meri vplivati na obe skupini, da bi bilo mogoče ugotoviti učinek zdravljenja.
• Untreated hypertension is associated with a significant risk of target organ damage.
• Nezdravljena hipertenzija povzroča pomembno tveganje okvare ciljnega organa.
Vasotop P 2,5 mg, tablet
Vasotop P 2,5 mg, tableta
Percentage of cats with different number of clinical signs and their response to the treatment
2.3 Delež mačk z različnim številom kliničnih znakov in njihov odziv na zdravljenje
Whilst none could be identified, the CVMP is concerned that the list of factors studied was hardly exhaustive, and in effect, only two such parameters were actually investigated (i.e. diet and concomitant treatment).
Ker le-teh ni bilo mogoče opredeliti, ima CVMP pomisleke, da je seznam proučevanih dejavnikov komaj dovolj izčrpen, poleg tega sta bila dejansko proučevana le dva takšna parametra (tj. prehrana in sočasno zdravljenje).
However, any clinical disease sees its signs evolve over the life of the animal and the duration of the clinical trial; it is the delta in the study that either decreases or increases spontaneously.
Vendar pa se pri vsaki klinični bolezni njeni znaki razvijajo v toku življenja živali in trajanja kliničnega preskušanja; to je delta v študiji, ki se spontano zmanjšuje ali povečuje.
Improvement in hypertension in the absence of a negative control group
2.5 Izboljšanje hipertenzije v odsotnosti negativne kontrolne skupine
The mean CV was approximately 3 % at all time points studied; these values were similar to the CV values reported in the literature by Snyder
Povprečen KV je bil v vseh proučevanih časovnih točkah približno 3 %; te vrednosti so bile podobne vrednostim KV, o katerih je v literaturi poročal Snyder
Therefore, the clinical signs as mentioned may resolve (except for complete retinal detachment).
To pomeni, da navedeni klinični znaki lahko minejo (razen popolnega odstopa mrežnice).
The CVMP considers that it would be less unethical to risk non-treatment of a small number of animal patients for a shorter time period than to authorise an un-efficacious product.
CVMP meni, da bi bilo manj neetično tvegati nezdravljenje majhnega števila obolelih živali za krajše časovno obdobje kot odobriti neučinkovito zdravilo.
It is agreed that the white coat effect, when big, is up to 20 % or so.
Ugotovljeno je, da znaša učinek bele halje največ približno 20 %.
The CVMP considered that due to the low case numbers and lack of comparative statistics, the main findings from this study were more “proof of concept” than proof of definitive clinical efficacy.
CVMP je menil, da so bili zaradi nizkega števila primerov in pomanjkanja primerjalnih statistik glavni rezultati te študije bolj „dokaz koncepta“ kot dokaz dokončne klinične učinkovitosti.
Thus, the benefit/risk assessment is deemed unfavourable for the proposed indication in cats.
Zato je ocena koristi in tveganj za predlagano indikacijo pri mačkah neugodna.
LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE VETERINARY MEDICINAL PRODUCTS, ANIMAL SPECIES, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDER IN THE MEMBER STATES
SEZNAM IMEN, FARMACEVTSKIH OBLIK, JAKOSTI ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI, ŽIVALSKIH VRST, POTI UPORABE IN IMETNIKOV DOVOLJENJA ZA PROMET Z ZDRAVILOM V DRŽAVAH ČLANICAH
GROUNDS FOR THE REFUSAL OF THE VARIATION OF THE MARKETING AUTHORISATIONS
PODLAGA ZA ZAVRNITEV SPREMEMBE DOVOLJENJ ZA PROMET
No statistical difference was observed in the distribution of clinical signs among cases when stratified by risk category (p=0.5296).
Pri porazdelitvi kliničnih znakov med primeri pri razvrstitvi v kategorije tveganja ni bilo opaziti statistične razlike (p = 0,5296).
It is agreed that the effect noted by the MAH in a follow-up response (see 2.3) is bigger than that.
Ugotovljeno je, da je učinek, ki ga je ugotovil imetnik dovoljenja za promet z zdravilom ob nadaljnjem spremljanju odziva (glejte 2.3), večji od te vrednosti.
“For the reduction of elevated systolic blood pressure (between 160 and 230 mm Hg) and the control of associated clinical signs.”
„Za zmanjšanje povišanega sistoličnega krvnega tlaka (med 160 in 230 mm Hg) in nadzor povezanih kliničnih znakov.“
In addition at Day 63, only 53 % of cats still exhibited at least one clinical sign.
Poleg tega je na 63. dan le 53 % mačk še vedno imelo najmanj en klinični znak.
The CVMP considered that it is important to emphasise that it is known from the literature that no one agent currently available is 100 % effective in the treatment of feline hypertension, and success rates of about 50 % are considered the norm.
CVMP je menil, da je pomembno poudariti dognanja iz literature, da nobeno trenutno razpoložljivo sredstvo ni 100 % učinkovito pri zdravljenju hipertenzije pri mačkah, stopnja uspeha približno 50 % pa velja za normo.
However, without direct comparison to a negative control group, it is not possible to say if this effect is due to treatment.
Vendar pa brez neposredne primerjave z negativno kontrolno skupino ni mogoče trditi, da so ti učinki posledica zdravljenja.
How big or small the effect of this placebo effect depends as much on the disease as it does on the clinical setting and can only be determined through comparison with another group.
Kako velik ali majhen je ta učinek placeba, je v enaki meri odvisno od bolezni in kliničnih okoliščin; določiti ga je mogoče le ob primerjavi z drugo skupino.
• Even a short placebo treatment of 28 or 63 days could be associated with irreversible pathological changes to organs such as the eye (e.g. detached retina/blindness).
• Že kratkotrajno zdravljenje s placebom 28 ali 63 dni lahko povzroči ireverzibilne patološke spremembe organov, npr. očesa (npr. odstop mrežnice/slepota).
In relation to the non-specific signs such as polyuria, polydipsia etc., the CVMP opinion is that it is plausible that a correlation exists between the improvement in blood pressure measurements and the resolution of such signs.
V zvezi z nespecifičnimi znaki, kot so poliurija, polidipsija itd., CVMP meni, da je možna korelacija med izboljšanjem vrednosti krvnega tlaka in izboljšanjem takšnih znakov.